THE ROLE OF HORMONES AND INFLAMMATORY MARKERS IN COGNITIVE FUNCTIONING OF SCHIZOPHRENIC PATIENTS

Krzysztof Krysta¹, Marek Krzystanek¹, Wiesław J. Cubała², Mariusz S. Wiglusz², Katarzyna Jakuszkowiak-Wojten², Maria Gałuszko-Węgielnik², Monika Czarnowska-Cubała², Joanna Szarmach², Adam Włodarczyk² & Małgorzata Janas-Kozik³

¹Department of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland
²Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland
³Developmental Age Clinical Ward, Department of Psychiatry and Psychotherapy, Medical University of Silesia,
John Paul II Pediatric Center, Sosnowiec, Poland

SUMMARY

Background: In the literature we can find evidence that immunological processes are involved the alterations of cognition in schizophrenic patients. Another factor, which may have an impact on cognitive domains in this clinical group are hormones.

Objective: The objective of this review was to explore studies, in which the role of both immunological and endocrine factors on cognitive functions in schizophrenia are analyzed.

Methods: The search of papers covering this topic in PubMed and Google Scholar was performed.

Results: The studies focusing on this co-relation are not numerous. The role such hormones like cortisol, insulin and sex hormones may be important in the immunomodulatory processes influencing cognition in schizophrenia.

Conclusions: More studies are necessary to confirm these possible co-relations.

Key words: immunological processes – hormones -, cognitive functions - schizophrenia

* * * * *

Introduction

The immunopathogenesis of schizophrenia was postulated already in the 90-ties (Holden et al. 1997). Since then a number of publications have appeared to support this hypothesis (Muller & Schwarz 2006, Na et al. 2014, Bedrossian et al. 2016, Dickerson et al. 2016, Krysta et al. 2017, Karanikas 2011, Suvisaari & Mantere 2013). Levels of interleukins IL-2 and IL-4, Il-6 and other inflammatory markers were found to be increased of schizophrenic patients (Watanabe et al. 2008, Muller 2017). In the literature we can also find evidence for the co-relations of immunological processes and cognition in schizophrenia. In their systematic review Ribeiro-Santos et al. (2014) proposed that such factors like microglial activation, monoaminergic imbalance, brain abnormalities and the kynurenine pathway may be possible mechanisms leading to cognitive impairment in this psychiatric disorder (Ribeiro-Santos et al. 2014). Dunne et al. (2017) suggested that the level of antiinflammatory cytokines like Iinterleukin-10 may be corelated with social cognition in schizophrenia (Dunne et al. 2017). Another group of literature reports focus on the influence of serum hormone levels and cognitive functioning in schizophrenia (Bratek et al. 2015, Moore et al. 2013, Li et al. 2015, Halari et al. 2004). Yuan et al. (2016) in a study involving first episode schizophrenia patients found that testosterone and estradiol may protect cognitive function against recession (Yuan et al. 2016). It is possible that some changes in sex hormone levels in men and women suffering from schizophrenia may lead to certain differences in cognitive functioning

(Bozikas et al. 2010, Krysta et al. 2013). According to other research reports a co-relation can be found between cortisol levels and cognition (Havelka et al. 2016). The objective of this review was to explore studies, in which the role of both immunological and endocrine factors on cognitive functions in schizophrenia are analyzed.

Hormones and inflammatory markers and cognition in schizophrenia

Chiappelli et al. (2015) performed a study, in which they measured how cognitive deficits might be related to abnormalities in stress response. The participants of their study were tested with a battery of neurocognitive tests. They found that acute cortisol response was inversely correlated with processing speed, and the poststress Interleukin-6 response was significantly and negatively correlated with working memory. Another observation from this study was an exacerbated immune response to stress in schizophrenic patiens, which typically is suppressed in helathy controls. One of the conlusions they draw is that dysregulated cortisolimmune interactions, which is observed in the poststress Interleukin-6 response, is linked to cognitive abnormalities in schizophrenia (Chiappelli et al. 2016). Dickinson and Harvey (2008) draw the attention to the link of type 2 diabetes and chronic inflammation to impaired cognitive performance in schizophrenia. They propose a hypothesis that insulin resistance interacting with inflammatory processes may be associated with cognitive deficits in schizophrenic patients (Dickinson

& Harvey 2008). An empirical basis for this can be an observation that an association between diabetes and cognitive functioning in schizophrenia was found in earlier studies (Dickinson et al. 2008). Observations from research results indicate that the use of estrogenic drugs may mimic the anti-inflammatory activity of 17beta-estradiol and have a beneficial effects against neurodegeneration (Pozzi et al. 2006). Weickert et al. (2016) in their study observed that the impact of sex hormones on cognitive functioning in schizophrenia may be different that in healthy controls. They discuss a possible role anti-inflammatory effects of oestrogen in the treatment of cognitive deficits (Weickert et al. 2016)

Conlusions

Clinical reports show benefits from augmenting antipsychotic treatment with estrogens or selective estrogen receptor modulators. Different mechanism of action of these drugs are discussed (Bratek et al. 2016). Although the literature data referring to the role of hormones and inflammatory markers is not very rich, we have some observations that some hormones, like estrogen may have and anti-inflammatory effects, which may be advantageous in the treatment of cognitive deficits (Weickert et al. 2016). The role of other hormones, like cortisol is also very important, as it is observed that the stress response resulting in inflammatory markers response schizophrenia may be linked to cognitive abnormalities in schizophrenia. However due to limited literature data the above conclusions must be cautious and more research studies are necessary to confirm these possible co-relations.

Acknowledgements: None.

Conflict of interest: None to declare.

Contribution of individual authors:

- Krysta K and Krzystanek M designed the concept of the manuscript and performed the search,
- Cubała WJ and Wiglusz MS derived and analysed the data.
- Jakuszkowiak Wojten K, with Czarnowska-Cubała M, Szarmach J and Włodarczyk A wrote the manuscript in consultation with Janas-Kozik M.

References

- Bedrossian N, Haidar M, Fares J, Kobeissy FH & Fares Y: Inflammation and Elevation of Interleukin-12p40 in Patients with Schizophrenia. Front Mol Neurosci 2016; 22:9:16.
- 2. Bozikas VP, Kosmidis MH, Peltekis A, Giannakou M, Nimatoudis I, Karavatos A, et al: Sex differences in neuropsychological functioning among schizophrenia patients. Aust NZ J Psychiatry 2010; 44:333-341.

- Bratek A, Kozmin-Burzynska A, Krysta K, Cierpka-Wiszniewska K & Krupka-Matuszczyk I: Effects of hormones on cognition in schizophrenic male patientspreliminary results. Psychiatr Danub 2015; 27 Suppl 1:S261-265.
- 4. Bratek A, Krysta K, Drzyzga K, Baranska J & Kucia K: The role of selective estrogen receptor modulators in the treatment of schizophrenia. Psychiatr Danub 2016; 28 Suppl 1:45-48.
- Chiappelli J, Shi Q, Kodi P, Savransky A, Kochunov P, Rowland LM, et al.: Disrupted Glucocorticoid - Immune Interactions During Stress Response in Schizophrenia. Psychoneuroendocrinology 2016; 63:86-93.
- Dickerson F, Stallings C, Origoni A, Schroeder J, Katsafanas E, Schweinfurth L, et al.: Inflammatory Markers in Recent Onset Psychosis and Chronic Schizophrenia. Schizophr Bull 2016; 42:134-41.
- 7. Dickinson D, Gold JM, Dickerson FB, Medoff D & Dixon LB: Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 2008; 49:123-131.
- 8. Dickinson D & Harvey PD: Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 2009; 35:403-414.
- 9. Dunne PW, Roberts DL, Quinones MP, Velligan DI, Paredes M, Walss-Bass C: Immune markers of social cognitive bias in schizophrenia. Psychiatry Res 2017; 251:319-324.
- 10. Halari R, Kumari V, Mehrotra R, Wheeler M, Hines M & Sharma T: The relationship of sex hormones and cortisol with cognitive functioning in Schizophrenia. J Psychopharmacol. 2004; 18:366-374.
- 11. Havelka D, Prikrylova-Kucerova H, Prikryl R, & Ceskova E: Cognitive impairment and cortisol levels in first-episode schizophrenia patients. Stress 20161; 19:383-389.
- 12. Holden RJ, Pakula IS & Mooney PA: A neuroimmunological model of schizophrenia and major depression: a review. Human Psychopharmacology: Clinical and Experimental 1997; 12:177-201.
- 13. Karanikas EP: Psycho-immunological mechanisms in schizophrenia. Psychiatriki 2011; 22:43-52.
- Krysta K, Krzystanek M, Bratek A & Krupka-Matuszczyk
 Sleep and inflammatory markers in different psychiatric disorders. J Neural Transm (Vienna) 2017; 124 Suppl 1:179-186.
- Krysta K, Murawiec S, Klasik A, Wiglusz MS & Krupka-Matuszczyk I: Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub 2013; 25 Suppl 2:S244-246.
- 16. Li J, Xiao W, Sha W, Xian K, Tang X & Zhang X: Relationship of serum testosterone levels with cognitive function in chronic antipsychotic-treated male patients with schizophrenia. Asia Pac Psychiatry 2015; 7:323-329.
- 17. Moore L, Kyaw M, Vercammen A, Lenroot R, Kulkarni J, Curtis J, et al.: Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 2013; 38:1717-1728.
- Muller N: Neuroprogression in Schizophrenia and Psychotic Disorders: The Possible Role of Inflammation. Mod Trends Pharmacopsychiatry 2017; 31:1-9.
- 19. Muller N & Schwarz M: Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006; 10:131-148.

- Na KS, Jung HY & Kim YK: The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48:277-286.
- 21. Pozzi S, Benedusi V, Maggi A & Vegeto E: Estrogen Action in Neuroprotection and Brain Inflammation. Ann N Y Acad Sci 2006; 1089:302-323.
- 22. Ribeiro-Santos R, Lucio Teixeira A & Vinicius Salgado J: Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol 2014; 12:273-80.
- 23. Suvisaari J & Mantere O: Inflammation theories in psychotic disorders: a critical review. Infect Disord Drug Targets 2013; 13:59-70.
- 24. Watanabe Y, Nunokawa A, Shibuya M, Kaneko N, Nawa H & Someya T: Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population. Eur Arch Psychiatry Clin Neurosci 2008; 258:422-427.
- 25. Weickert TW, Allen KM & Weickert CS: Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia. CNS Drugs 2016; 30:125-133.
- 26. Yuan XX, Zhu QY, Liang HB, Hei GR, Li X, Pang LJ, et al.: Correlations between hormone levels and psychiatric symptoms as well as cognitive function in drug-free firstepisode schizophrenics. Zhonghua Yi Xue Za Zhi 2016; 19:2155-2160.

Krzysztof Krysta, MD Department of Rehabilitation Psychiatry, Medical University of Silesia Ziołowa 45/47, 40-635 Katowice, Poland E-mail: krysta@mp.pl